Company intelligence / Profile preview

Chronos Equity

Oxford, England, United Kingdomchronos-equity.com ↗

Ownership: Private
Development stage: Other

Overview

Chronos developed small molecule drugs targeting neurological diseases of aging using its proprietary phenotypic screening platform. Its lead compound RDC5 advanced to Phase 2 trials in ALS and osteoporosis. In recent years it focused on CNS/neuropsychiatry with Ox1 antagonist (anxiety/addiction) and DAT inhibitor (fatigue/narcolepsy), both at late preclinical stage. The company was acquired by Evgen Pharma in March 2024; some assets will be advanced within Evgen’s pipeline with first clinical readouts expected from combined group around 2026–2027.

Therapeutic areas: PsychiatryNeurologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Shire/Takeda (acquisition of three CNS programs from Shire/Takeda subsidiary)Stalicla SA (out-license deal for neurodevelopmental disorder program via new parent Evgen)Academic collaborations including University of Oxford

Beyond the preview

Go deeper on Chronos Equity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chronos Equity.

Explore the full profile